2022. Low Risk of Serious Infections and Infections of Interest in Psoriasis Patients Treated with Guselkumab (GUS) for up to 5 Years in VOYAGE (VOY) 1&2 Phase 3 Trials. SKIN The Journal of Cutaneous Medicine. 6, 2 (Mar. 2022), s1. DOI:https://doi.org/10.25251/skin.6.supp.1.